A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

153 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Multicenter, Randomized, Open-labeled, Cross-over, Active-controlled, Phase IV Clinical Trial to Evaluate the Preference of Formulation and the Efficacy and Safety of Renamezin and Kremezin in Pre-dialysis Patients With Chronic Renal Failure

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase Ⅳ Clinical Trial to Evaluate of Renamezin in Patients With Chronic Renal Failure.

NCT02681991

Chronic Renal Failure

COMPLETED PHASE4

Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis

NCT01736150

Chronic Kidney Disease Chronic Kidney Disease on Hemodialysis

COMPLETED PHASE3

Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment

NCT04154670

Healthy Renal Insufficiency

COMPLETED PHASE1

Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT03281538

Uremic Pruritus

COMPLETED PHASE3

Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus

NCT02858726

Uremic Pruritus

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Renal Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Renamezin->Kremezin

Group Type ACTIVE_COMPARATOR

Renamezin capsule

Intervention Type DRUG

Kremezin granule

Intervention Type DRUG

Kremezin->Renamezin

Group Type ACTIVE_COMPARATOR

Renamezin capsule

Intervention Type DRUG

Kremezin granule

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Renamezin capsule

Intervention Type DRUG

Kremezin granule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* pre-dialysis patients with chronic renal failure stage
* patient for holding the stable state in serum creatinine 2.0mg/dl - 5.0mg/dl of MDRD GFR 15-60ml/min/1.73m2 for 3 months before screening
* patients haven't experienced dose spherical carbon adsorbent for 3months before screening
* patients who were no noticeable change for 4weeks before screening and are expected to change is not needed during therapy in the therapy of chronic renal failure(type of blood pressure medication and dose -related, diet therapy)
* patients spontaneously written consent to participate in this clinical trial

Exclusion Criteria

* patients with passes through the digestive tract disorders
* patients with uncontrolled constipation symptoms
* kidney transplant patients
* patients who are taking immunosuppressive drugs
* patients suffering from digestive tract ulcers and esophageal varices
* patients with uncontrolled hypertension
* patients hospitalized with cardiovascular disease within 3 months of the screening
* patients with current infections
* patients who do not fulfill therapies of chronic renal failure (taking medicine and diet) as appropriate
* patients with hepatic impairment (2.5 times greater than the upper limit of normal levels of AST, ALT)
* uncontrolled diabetes (HbA1c \> 10 % or a fasting glucose \> 180mg / dL)
* patients with malignant tumors (However, if you do not relapse within five years after completion of therapy can be registered)
* pregnant women, nursing mothers
* those who do not agree to a contraceptive method allowed for the possibility of pregnancy in women
* patients participating in another clinical trial in addition to the current clinical trial
* subjects with dependency on drugs or alcohol
* subjects who took any other investigational drugs within 30 days before participating this clinical trial study
* patients expected to starting the dialysis within three months
* other patients deemed unsuitable tester

Minimum Eligible Age

20 Years

Maximum Eligible Age

74 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No